Kolon Kanserli Hastalarda Post-Operatif Adjuvan Kemoterapide Kapesitabinin Tolerabilitesi: Tek Merkezli Çalışma

Esat Namal; Özgül Pamukçu Cerciz; Pelin Altınok Süt; Bülent Askaroğlu; Betül Yildiz

Araştırma Makalesi

Kolon Kanserli Hastalarda Post-Operatif Adjuvan Kemoterapide Kapesitabinin Tolerabilitesi: Tek Merkezli Çalışma

Yıl 2018, Cilt: 7 Sayı: 1, 35 - 39, 31.03.2018

Esat Namal , Özgül Pamukçu Cerciz , Pelin Altınok Süt Bülent Askaroğlu Betül Yildiz

Öz

X-ACT (Xeloda in
Adjuvant Colon Cancer Therapy) Çalışması’na göre kapesitabin kolon
kanserlerinde adjuvan kemoterapide standart bir tedavi haline gelmiş
bulunmaktadır. Ancak, biz kendi pratiğimizde kapesitabinin daha sık yan etkisi
bulunduğunu gözlemlemekteyiz. Çalışmamızda
karşılaştığımız yan etki profilini sunarak kapesitabin kullanımının klinik
pratikte farklı sonuçlarla karşımıza gelebileceğini göstermeyi hedefledik. Çalışmamızda, kolon
kanserli 89 hastamızın küratif rezeksiyon sonrası kapesitabin ile postoperatif
8 siklus adjuvan kapesitabin kemoterapisi sırasında gelişen yan etkileri ve
buna bağlı tedavi sonlandırılma gereksinimlerini retrospektif olarak inceledik. Çalışmaya alınan 89
hastanın 82’si tedavi sikluslarını tamamlamış olup 3'ü 6 siklus; 2’si ise 3
siklus sonunda tedaviyi bırakmışlardır. Başlangıç dozu her hasta tarafından
tolere edilmiş ancak tüm hastalarda tedavi süresince doz azaltımına
gidilmiştir. Çalışmamızda, kapesitabinin
önerilen dozlarını toksisite nedeniyle hiçbir hastamızın tolere edemediği ortaya
konmuştur. X-ACT Çalışması’nda kapesitabinin daha az yan etki ile
ilişkilendirilmiş olmasına karşın bizler çalışmamızda bu durumun aksini
gözlemlemiş bulunmaktayız.

Anahtar Kelimeler

kapesitabin, kolon, kanser

Kaynakça

1. Statistics From the National Health In-terview Survey. (2015, November 19). Retrieved September 07, 2017, from https://nccih.nih.gov/research/statistics/NHIS
2. Compton, C., Fenoglio-Preiser, C. M., Pettigrew, N., & Fielding, L. P. (2000). American Joint Committee on Cancer prognostic factors consensus conferen-ce. Cancer,88(7), 1739-1757. doi:10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t
3. Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J. et al. (2004). American So-ciety of Clinical Oncology Recommenda-tions on Adjuvant Chemotherapy for Stage II Colon Cancer. Journal of Clini-cal Oncology,22(16), 3408-3419. doi:10.1200/jco.2004.05.063
4. Bensoniii, A. (2005). Adjuvant Chemot-herapy of Stage III Colon Can-cer. Seminars in Oncology,32, 74-77. doi:10.1053/j.seminoncol.2005.04.016
5. Purandare, L. (2012). Follow-up to the MOSAIC study (multicentre internatio-nal study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon can-cer). Http://isrctn.org/>. doi:10.1186/isrctn38080578
6. Twelves, C., Wong, A., Nowacki, M., Abt, M., & Burris, H. (2006). Capécita-bine et traitement adjuvant des cancers du côlon. Gastroentérologie Clinique et Biologique,30(1), 169-170. doi:10.1016/s0399-8320(06)73144-x
7. Basch, E., Jia, X., Heller, G., Barz, A., Sit, L., Fruscione, M., et al. (2009). Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes. JNCI: Journal of the National Cancer Institu-te,101(23), 1624-1632. doi:10.1093/jnci/djp386
8. Walko, C. M., & Lindley, C. (2005). Ca-pecitabine: A review. Clinical Therapeu-tics,27(1), 23-44. doi:10.1016/j.clinthera.2005.01.005.
9. Liu, G., Franssen, E., Fitch, M. I., & Warner, E. (1997). Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Onco- logy,15(1), 110-115. doi:10.1200/jco.1997.15.1.110
10. Diaz-Rubio, E. (2002). Capecitabine (Xeloda(R)) in combination with oxalip-latin: a phase I, dose-escalation study in patients with advanced or metastatic so-lid tumors. Annals of Oncology,13(4), 558-565. doi:10.1093/annonc/mdf065
11. Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., et al (2004). XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer. Journal of Clinical Onco-logy,22(11), 2084-2091. doi:10.1200/jco.2004.11.069
12. Jordan, K., Kellner, O., Kegel, T., Sch-moll, H., & Grothey, A. (2004). Phase II Trial of Capecitabine/Irinotecan and Ca-pecitabine/Oxaliplatin in Advanced Gastrointestinal Cancers. Clinical Colo-rectal Cancer,4(1), 46-50. doi:10.3816/ccc.2004.n.009
13. Grothey, A., & Schmoll, H. (2001). New chemotherapy approaches in colorectal cancer. Current Opinion in Onco-logy,13(4), 275-286. doi:10.1097/00001622-200107000-00011
14. Schmoll, H., & Arnold, D. (2006). Upda-te on Capecitabine in Colorectal Can-cer. The Oncologist,11(9), 1003-1009. doi:10.1634/theoncologist.11-9-1003
15. Cutsem, E. V., Hoff, P. M., Harper, P., Bukowski, R. M., Cunningham, D., Du-four, P., et al. (2004). Oral capecitabine vs intravenous 5-fluorouracil and leuco-vorin: integrated efficacy data and no-vel analyses from two large, randomised, phase III trials. British Journal of Can-cer,90(6), 1190-1197. doi:10.1038/sj.bjc.6601676
16. Cassidy, J. (2002). First-line oral cape-citabine therapy in metastatic colorectal cancer: a favorable safety profile com-pared with intravenous 5-fluorouracil/leucovorin. Annals of Onco-logy,13(4), 566-575. doi:10.1093/annonc/mdf089
17. Twelves, C., Scheithauer, W., Mckend-rick, J., Seitz, J. F., Hazel, G. V., Wong, A., et al (2011). Capecitabine versus 5-fluorouracil/folinic acid as ad-juvant therapy for stage III colon can-cer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Annals of Oncology,23(5), 1190-1197. doi:10.1093/annonc/mdr366
18. Díaz-Rubio, E., Tabernero, J., Gómez-España, A., Massutí, B., Sastre, J., Cha-ves, M.,et al (2007). Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. Journal of Clinical Onco-logy,25(27), 4224-4230. doi:10.1200/jco.2006.09.8467
19. Ducreux, M., Bennouna, J., Hebbar, M., Ychou, M., Lledo, G., Conroy, T., . . . Douillard, J. (2010). Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal can-cer. International Journal of Can-cer,128(3), 682-690. doi:10.1002/ijc.25369
20. Hochster, H. S., Hart, L. L., Ramanat-han, R. K., Childs, B. H., Hainsworth, J. D., Cohn, A. L.,et al (2008). Safety and Efficacy of Oxaliplatin and Fluo-ropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study. Journal of Clinical On-cology,26(21), 3523-3529. doi:10.1200/jco.2007.15.4138

Yıl 2018, Cilt: 7 Sayı: 1, 35 - 39, 31.03.2018

Esat Namal , Özgül Pamukçu Cerciz , Pelin Altınok Süt Bülent Askaroğlu Betül Yildiz

Öz

Kaynakça

1. Statistics From the National Health In-terview Survey. (2015, November 19). Retrieved September 07, 2017, from https://nccih.nih.gov/research/statistics/NHIS
2. Compton, C., Fenoglio-Preiser, C. M., Pettigrew, N., & Fielding, L. P. (2000). American Joint Committee on Cancer prognostic factors consensus conferen-ce. Cancer,88(7), 1739-1757. doi:10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t
3. Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J. et al. (2004). American So-ciety of Clinical Oncology Recommenda-tions on Adjuvant Chemotherapy for Stage II Colon Cancer. Journal of Clini-cal Oncology,22(16), 3408-3419. doi:10.1200/jco.2004.05.063
4. Bensoniii, A. (2005). Adjuvant Chemot-herapy of Stage III Colon Can-cer. Seminars in Oncology,32, 74-77. doi:10.1053/j.seminoncol.2005.04.016
5. Purandare, L. (2012). Follow-up to the MOSAIC study (multicentre internatio-nal study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon can-cer). Http://isrctn.org/>. doi:10.1186/isrctn38080578
6. Twelves, C., Wong, A., Nowacki, M., Abt, M., & Burris, H. (2006). Capécita-bine et traitement adjuvant des cancers du côlon. Gastroentérologie Clinique et Biologique,30(1), 169-170. doi:10.1016/s0399-8320(06)73144-x
7. Basch, E., Jia, X., Heller, G., Barz, A., Sit, L., Fruscione, M., et al. (2009). Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes. JNCI: Journal of the National Cancer Institu-te,101(23), 1624-1632. doi:10.1093/jnci/djp386
8. Walko, C. M., & Lindley, C. (2005). Ca-pecitabine: A review. Clinical Therapeu-tics,27(1), 23-44. doi:10.1016/j.clinthera.2005.01.005.
9. Liu, G., Franssen, E., Fitch, M. I., & Warner, E. (1997). Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Onco- logy,15(1), 110-115. doi:10.1200/jco.1997.15.1.110
10. Diaz-Rubio, E. (2002). Capecitabine (Xeloda(R)) in combination with oxalip-latin: a phase I, dose-escalation study in patients with advanced or metastatic so-lid tumors. Annals of Oncology,13(4), 558-565. doi:10.1093/annonc/mdf065
11. Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., et al (2004). XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer. Journal of Clinical Onco-logy,22(11), 2084-2091. doi:10.1200/jco.2004.11.069
12. Jordan, K., Kellner, O., Kegel, T., Sch-moll, H., & Grothey, A. (2004). Phase II Trial of Capecitabine/Irinotecan and Ca-pecitabine/Oxaliplatin in Advanced Gastrointestinal Cancers. Clinical Colo-rectal Cancer,4(1), 46-50. doi:10.3816/ccc.2004.n.009
13. Grothey, A., & Schmoll, H. (2001). New chemotherapy approaches in colorectal cancer. Current Opinion in Onco-logy,13(4), 275-286. doi:10.1097/00001622-200107000-00011
14. Schmoll, H., & Arnold, D. (2006). Upda-te on Capecitabine in Colorectal Can-cer. The Oncologist,11(9), 1003-1009. doi:10.1634/theoncologist.11-9-1003
15. Cutsem, E. V., Hoff, P. M., Harper, P., Bukowski, R. M., Cunningham, D., Du-four, P., et al. (2004). Oral capecitabine vs intravenous 5-fluorouracil and leuco-vorin: integrated efficacy data and no-vel analyses from two large, randomised, phase III trials. British Journal of Can-cer,90(6), 1190-1197. doi:10.1038/sj.bjc.6601676
16. Cassidy, J. (2002). First-line oral cape-citabine therapy in metastatic colorectal cancer: a favorable safety profile com-pared with intravenous 5-fluorouracil/leucovorin. Annals of Onco-logy,13(4), 566-575. doi:10.1093/annonc/mdf089
17. Twelves, C., Scheithauer, W., Mckend-rick, J., Seitz, J. F., Hazel, G. V., Wong, A., et al (2011). Capecitabine versus 5-fluorouracil/folinic acid as ad-juvant therapy for stage III colon can-cer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Annals of Oncology,23(5), 1190-1197. doi:10.1093/annonc/mdr366
18. Díaz-Rubio, E., Tabernero, J., Gómez-España, A., Massutí, B., Sastre, J., Cha-ves, M.,et al (2007). Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. Journal of Clinical Onco-logy,25(27), 4224-4230. doi:10.1200/jco.2006.09.8467
19. Ducreux, M., Bennouna, J., Hebbar, M., Ychou, M., Lledo, G., Conroy, T., . . . Douillard, J. (2010). Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal can-cer. International Journal of Can-cer,128(3), 682-690. doi:10.1002/ijc.25369
20. Hochster, H. S., Hart, L. L., Ramanat-han, R. K., Childs, B. H., Hainsworth, J. D., Cohn, A. L.,et al (2008). Safety and Efficacy of Oxaliplatin and Fluo-ropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study. Journal of Clinical On-cology,26(21), 3523-3529. doi:10.1200/jco.2007.15.4138

Toplam 20 adet kaynakça vardır.

Ayrıntılar

Birincil Dil	Türkçe
Konular	Sağlık Kurumları Yönetimi
Bölüm	Araştırma Makaleleri
Yazarlar	Esat Namal 0000-0002-3365-4348 Özgül Pamukçu Cerciz 0000-0002-3365-4348 Pelin Altınok Süt Bu kişi benim 0000-0002-3365-4348 Bülent Askaroğlu Bu kişi benim 0000-0002-3365-4348 Betül Yildiz Bu kişi benim 0000-0002-3365-4348
Yayımlanma Tarihi	31 Mart 2018
Yayımlandığı Sayı	Yıl 2018 Cilt: 7 Sayı: 1

Kaynak Göster

APA	Namal, E., Pamukçu Cerciz, Ö., Altınok Süt, P., Askaroğlu, B., vd. (2018). Kolon Kanserli Hastalarda Post-Operatif Adjuvan Kemoterapide Kapesitabinin Tolerabilitesi: Tek Merkezli Çalışma. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi, 7(1), 35-39.
AMA	Namal E, Pamukçu Cerciz Ö, Altınok Süt P, Askaroğlu B, Yildiz B. Kolon Kanserli Hastalarda Post-Operatif Adjuvan Kemoterapide Kapesitabinin Tolerabilitesi: Tek Merkezli Çalışma. Gümüşhane Sağlık Bilimleri Dergisi. Mart 2018;7(1):35-39.
Chicago	Namal, Esat, Özgül Pamukçu Cerciz, Pelin Altınok Süt, Bülent Askaroğlu, ve Betül Yildiz. “Kolon Kanserli Hastalarda Post-Operatif Adjuvan Kemoterapide Kapesitabinin Tolerabilitesi: Tek Merkezli Çalışma”. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi 7, sy. 1 (Mart 2018): 35-39.
EndNote	Namal E, Pamukçu Cerciz Ö, Altınok Süt P, Askaroğlu B, Yildiz B (01 Mart 2018) Kolon Kanserli Hastalarda Post-Operatif Adjuvan Kemoterapide Kapesitabinin Tolerabilitesi: Tek Merkezli Çalışma. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi 7 1 35–39.
IEEE	E. Namal, Ö. Pamukçu Cerciz, P. Altınok Süt, B. Askaroğlu, ve B. Yildiz, “Kolon Kanserli Hastalarda Post-Operatif Adjuvan Kemoterapide Kapesitabinin Tolerabilitesi: Tek Merkezli Çalışma”, Gümüşhane Sağlık Bilimleri Dergisi, c. 7, sy. 1, ss. 35–39, 2018.
ISNAD	Namal, Esat vd. “Kolon Kanserli Hastalarda Post-Operatif Adjuvan Kemoterapide Kapesitabinin Tolerabilitesi: Tek Merkezli Çalışma”. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi 7/1 (Mart 2018), 35-39.
JAMA	Namal E, Pamukçu Cerciz Ö, Altınok Süt P, Askaroğlu B, Yildiz B. Kolon Kanserli Hastalarda Post-Operatif Adjuvan Kemoterapide Kapesitabinin Tolerabilitesi: Tek Merkezli Çalışma. Gümüşhane Sağlık Bilimleri Dergisi. 2018;7:35–39.
MLA	Namal, Esat vd. “Kolon Kanserli Hastalarda Post-Operatif Adjuvan Kemoterapide Kapesitabinin Tolerabilitesi: Tek Merkezli Çalışma”. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi, c. 7, sy. 1, 2018, ss. 35-39.
Vancouver	Namal E, Pamukçu Cerciz Ö, Altınok Süt P, Askaroğlu B, Yildiz B. Kolon Kanserli Hastalarda Post-Operatif Adjuvan Kemoterapide Kapesitabinin Tolerabilitesi: Tek Merkezli Çalışma. Gümüşhane Sağlık Bilimleri Dergisi. 2018;7(1):35-9.

Makale Dosyaları

Tam Metin